With a mission of providing the most leading-edge cancer care available, CARTI’s medical team actively participates in research projects that will impact the treatment options we are able to provide our current and future patients. The purpose of our research is to engage in research-driven patient care by offering the most effective new treatment options in order to extend survival, improve quality of life and advance the knowledge of cancer treatment. CARTI’s Research Department hosts clinical trials focused on improving cancer detection, treatment and supportive care.
- The research team is led by Dr. Kamal Patel.
- Other Principal Investigators include: Dr. Ryan Hall, Dr. Rhonda Gentry, Dr. Lawrence Mendelsohn, Dr. David Hays, Dr. Edgar St. Amour, Dr. Stacy Smith-Foley and Dr. Christopher Pope
- To make our clinical trials available to all CARTI patients, all of our physicians serve as sub-investigators.
OPEN RESEARCH PROJECTS
The department is currently working with pharmaceutical companies on over 25 clinical trials to examine the safety and efficacy of new treatments, reduce the time between treatment and response evaluation, improve supportive care medications, monitor treatments in the real world setting and provide biological samples to develop tests for early cancer detection.
HOW TO PARTICIPATE IN A CLINICAL TRIAL
If you are interested in participating in a clinical trial, ask your physician if you qualify.
Participation in research is always voluntary. For further information on clinical trials, please visit http://www.clinicaltrials.gov.
- CARTI to Serve as First Center in US to Treat Patients Through Embrace Hydrogel Embolic System Global Randomized Multi-Center Clinical Trial
ABSTRACTS BY CARTI PHYSICIANS
- Phase IIIb Safety and Efficacy of Intravenous Nepa for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. Kamal Patel, M.D., The Oncologist.
- Mortality and Causes of Death for Patients with Polycythemia Vera: Analysis of the REVEAL Prospective, Observational Study. Kamal Patel, M.D., American Society of Hematology.
- Demographics, Prior Therapies and Reasons for Cemiplimab Treatment: Prospective CemiplimAb-rwlc Survivorship and Epidemioogy (C.A.S.E.) Study in Patients with Advanced Cutaneous Squamous Cell Carcinoma. Rhonda Gentry, M.D.
- The Right to Try, Kamal Patel, M.D., The Healthcare Journal of Arkansas.
If you have any additional questions about CARTI’s Research Department, please call 501.906.3012 or email Research@CARTI.com.